GSK's Application for Jemperli's Expanded Indication Accepted by FDA for Priority Review
GSK (GSK) said Wednesday that the US Food and Drug Administration granted priority review to its supplemental Biologics License Application for Jemperli in combination with chemotherapy to expand trea
MT NewswiresApr 24 10:38 ET
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix
GSK (GSK) on Wednesday reported positive results from phase 3 trials for gepotidacin, an oral antibiotic to treat urogenital gonorrhea, and Shingrix, its shingles vaccine. The drug maker said gepotida
MT NewswiresApr 17 09:18 ET
GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial
British drugmaker GSK (GSK.L) on Wednesday said a phase 3 trial of its gepotidacin drug for treating uncomplicated urogenital gonorrhea in adolescents and adults met its primary endpoint. The oral ant
MT NewswiresApr 17 03:13 ET
GSK Says US FDA Accepts Meningococcal Vaccine Candidate for Regulatory Review
GSK (GSK) said in a regulatory filing Tuesday that the US Food and Drug Administration has accepted for review the company's biologics license application for its meningococcal ABCWY vaccine candidate
MT NewswiresApr 16 08:14 ET
GSK PLC Sponsored ADR (GSK) Is Attracting Investor Attention: Here Is What You Should Know
Yahoo FinanceMar 28 09:00 ET
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
Yahoo FinanceMar 13 09:40 ET
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
Yahoo FinanceMar 7 12:00 ET
Guggenheim Lifts GSK to Buy on Improved Growth Outlook
Guggenheim analysts upgraded GSK plc (GLAFX) to Buy from Neutral on Monday, citing “key revenue updates” and “increased confidence in margin benefits, pointing to upside potential” in the company’s shares.
Investing.com Mar 4 09:58 ET
Investors Heavily Search GSK PLC Sponsored ADR (GSK): Here Is What You Need to Know
Yahoo FinanceFeb 29 09:00 ET
GSK PLC Reaches Confidential Settlement With Boyd/Steenvoord in Zantac Litigation
GSK PLC Reaches Confidential Settlement With Boyd/Steenvoord in Zantac Litigation
Dow JonesFeb 29 02:01 ET
Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?
Yahoo FinanceFeb 26 09:40 ET
Gonorrhoea Pill Trial Results Hailed as Drug Resistance Grows
Yahoo FinanceFeb 26 08:57 ET
New Gonorrhea Pill Is as Good as Injected Antibiotic, GSK Says
A new antibiotic pill for gonorrhea was as good as current treatments in a late stage trial for an infection that has resurfaced around the globe, the drugmaker GSK Plc said.
BNN BloombergFeb 26 02:51 ET
Moderna CEO: 2024 Is Year of Growth, With 2023 Transition in Rearview
Yahoo FinanceFeb 22 11:22 ET
GSK Says HIV Shot Is Better Than Daily Pills for Some Patients
GSK Plc’s long-acting HIV drug worked better than daily pills for some patients, especially those who have trouble adhering to a treatment schedule, according to a unit of the UK pharmaceutical company.
BNN BloombergFeb 21 02:21 ET
GSK PLC GSK Completes Acquisition of Aiolos Bio
GSK PLC GSK Completes Acquisition of Aiolos Bio
Dow JonesFeb 15 02:00 ET
GSK PLC Target Raised to GBP21 From GBP17 by Citigroup
GSK PLC Target Raised to GBP21 From GBP17 by Citigroup
Dow JonesFeb 13 04:30 ET
GSK Seeks FDA Approval for RSV Vaccine in Adults 50-59
GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration (FDA) is reviewing an application for the extension of their adjuvanted respiratory syncytial virus (RSV) vaccine, currently approved for adults over 60, to include adults aged 50-59 with increased risk for RSV disease.
Investing.com Feb 6 07:22 ET
GSK's RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
Yahoo FinanceFeb 6 07:00 ET
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk Plc
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We adjust our target price by USD4 to US
MT NewswiresFeb 1 00:10 ET
No Data
No Data